1

1

2014 First-half resultsAnalysts’ & Media ConferenceBasel, 26 August 2014

2

This presentation contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. Straumann is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

The availability and indications/claims of the products illustrated and mentioned in this presentation may vary according to country.

Disclaimer

2

First-half highlightsMarco Gadola, CEO

Strong financial and strategic progress

4

REVENUE BEST PERFORMERS GROSS MARGIN

CHF 359m APAC & ROW 78.9%

H1: +5% (organic) Q2: +3% (organic) Double-digit growth in both regions

+1.6% points (excl. FX) driven by strong implant volumes, optimized plant utilization and product mix

EBIT MARGIN TOTAL SOLUTION PROVIDER GROWTH STRATEGY

20.9% Portfolio expansionGeographic and segment expansion

Underlying margin1 improved 4.2% points driven by improved gross profit and reduced OPEX

New prosthetics range launched, new generation tapered implant, full regenerative range, innovation leadership

Investments in China and ‘value-brand’ platform

1 Excluding exceptionals in prior year and currency exchange rate effects2 The term ‘organic’ in this presentation means excluding the effects of acquisitions, divestitures and currency exchange rates

3

2014 guidance

Rightsizing and re-organisation

measures

* Straumann, Nobel Biocare, Zimmer Dental, Biomet 3i, Dentsply Implants - based on company and SEC reports as well as management comments.

5

Fifth consecutive quarter of above-market growth

1Straumann, Nobel Biocare, Zimmer Dental, Biomet 3i, Dentsply Implants, based on company and SEC reports, as well as management comments. 5

Q2: revenue of CHF 179mn (+3% in l.c.)

Easter effect

-12%

-10%

-8%

-6%

-4%

-2%

0%

2%

4%

6%

8%

10%

Market for tooth replacement & restoration (leading implant companies)

Straumann l.c. growth

1

6

Share price reflects restored confidence

Source: Thomson Reuters Datastream

STMN N            SMI rebased            MSCI World rebased

Relative share price development in the past 5 years

...and over the past 2 years

4

Business and regional reviewThomas Dressendörfer, CFO

8

Margin expansion at all levels

in CHF million H1 2014

reported reported excl. except ionals excl.

except ionals and FX

reportedexcl.

exceptionals and FX

Revenue 359.1 354.8 343.4

YoY change 1.2% (1.9%) (1.7%) 4.6%

Gross profit 283.4 276.2 265.5 6.7%

margin 78.9% 77.8% 77.3% 110 bps 160 bps

EBITDA 88.8 74.5 80.1 74.7 18.9%

margin 24.7% 21.0% 22.6% 21.7% 370 bps 300 bps

EBIT 75.0 56.8 62.4 57.2 31.1%

margin 20.9% 16.0% 17.6% 16.7% 490 bps 420 bps

Net profit 68.7 53.7 48.5 41.7%

margin 19.1% 15.1% 14.1% 400 bps 500 bps

Basic EPS 4.42 3.48

Free Cash Flow 37.6 34.7

margin 10.5% 9.8%

Change (rounded)

H1 2013

5

77.8%

(0.5%)

77.3%

0.8%

1.2% (0.4%)

78.9%

H1 gross profitmargin

FX effect Adj. H1 grossprofit margin

Price / volume /mix

Inventory change COGS (highervolumes)

H1 gross profitmargin

In % of revenue, rounded

Higher implant sales and efficiency gains lift gross profit margin

91 Change in finished and semi-finished goods in H1 2014 compared with prior year

1

20142013

+160 bps

16.0%

(0.9%) 1.6%

16.7%

1.6%

2.6% 0.0%

20.9%

Reported H1EBIT

FX effect Restructuringcosts

Adjusted H1EBIT

Gross marginimprovement

OPEX reduction Other income Reported H1EBIT

EBIT margin clears 20% threshold

10

+420 bps

20142013

1 Exceptional costs of CHF 6 million related to last year’s cost optimization measures

In % of revenue, rounded

1

10

6

34.7

7.2

27.0 (24.7)

0.4 (3.0)(4.0)

37.6

Free cash flowH1 2013

Improved grossprofit

Lower cash-OPEX

Higher workingcapital

Lower CAPEX Higher interestpaid

Various Free cash flowH1 2014

Higher profitability drives cash flow

FCF margin 10.5%

FCF margin 9.8%

In CHF million, rounded

11 Chart shows cash-flow-relevant changes between 31 Dec 2013 and 30 June 2014 compared with prior year period

Increase mainly due to severance payment accruals

in H1 2013

+4 days: ‘Days of sales’+8 days: ‘Days of supplies’

11

354.8

(11.3)

343.5

2.64.6

5.52.9

359.1

Revenue H1 FX Effect Revenue H1 @FX 2014

Europe North America APAC ROW Revenue H1

5.3%1.4% 12.2% 18.6%

Change in l.c.

12

Growth across all regions

(3.3%)

4.6% in l.c.

In CHF million, rounded

1.2% in CHF

2013 2014

7

Good performance in N. America; Europe reflectsearly Easter in 2013

56%

Softer Q2 reflects Easter effect mainly in Central Europe

Encouraging growth in France, UK and Iberia

Soft Q2 in Turkish and Russian distributor market

(1.5%)

4.1%

(1.4%)(3.4%)

0.2%

(7.7%)

Q2 2014Q1 2014Q4 2013Q3 2013Q2 2013Q1 2013

Eu

rop

eN

ort

h A

mer

ica Q2 +5% on top of strong

comparative period in 2013

Mid-single-digit growth in North America

FX changes reduce regional growth in CHF by 6%-points

Revenue change (organic)

26%

13

5.4% 5.2%

11.0% 9.1%

10.6%

2.1%

Q2 2014Q1 2014Q4 2013Q3 2013Q2 2013Q1 2013

55%

Boost from emerging markets

56%

Double-digit growth driven by China and Japan

SLActive Tissue Level stimulates growth; SLActive Bone Level to launch in Q3

Currency headwind (mainly JPY) cuts regional growth in CHF by 8%-points

15.3%

8.3%

16.3%

7.9%

0.9%

-4.4%

Q2 2014Q1 2014Q4 2013Q3 2013Q2 2013Q1 2013

Asi

aP

acif

icR

est

of

Wo

rld

9.0%

28.6%

1.8%

35.1%

4.1%-2.6%

Q2 2014Q1 2014Q4 2013Q3 2013Q2 2013Q1 2013

Q2 +9%; sales fluctuation due to erratic distributor ordering

Strong performance by Straumann Brazil; Neodent posts high single-digit growth

Mexico and distributor markets continued to grow well, but less than in exceptionally strong Q1

14%

5%

14

Revenue change (organic)

8

Implants

Strong implant volume growth as the main driver

Restorative Regeneratives

1515

Our key strategic priorities to address changed market dynamics

Marco Gadola, CEO

9

Tracking the progress of our key priorities

17

Lean, high performance organization

Address changed market dynamics

Target unexploited growth markets

Cost reduction measures

New organization with increased customer focus

Continuing cost discipline

Customer- and market-driven Solutions

Immediate edentulous solutions

New tapered implant Ceramic implant Innovative Smileloc More CARES solutions Full regenerative range

Increase presence in fast-growing underpenetrated markets

Distribution take-over & new hybrid approach in China

Address value segment

Instradent set up and Neodent rolled-out

Investments in MegaGen & Biodenta

Covering the remaining white spots

Surgeons / Prosthodontists

GPs

Premium

Value

New ceramicimplant

Roxolid/SLActive 4mm implant

Single tooth Multiple tooth Edentulous

Ceramic implants

Simpleedentulous solutions

Implants for narrow spaces

Esthetic, fast implant solutions with single crown / small bridge

Low-tech

High-tech

18

Straumann ONE

Straumann Variobase

Cost-effective, open platform restoration

Bubble sizes illustrate market volume potential

BLT implant & enhance screw-retained prosthetics

Standard implant solution

packages

Fixed immediate edentulous solutions

Smaller, less invasive implants

18

10

19

CADCAM sub-structure embedded in fixed full-arch prosthesis

New prosthetics and Bone Level Tapered implant enhance immediate edentulous solutions

New range of screw-retained implant abutments offering increased flexibility

New Bone Level Tapered implants

Tapered implants are increasingly popular and account for more than 50% of the global implant market1

Combination of Roxolid, SLActive and Straumann design make this a new generation BLT implant with high strength, short healing time and a wide range of reliable prosthetic options

Handling benefits and good primary stability meet customer needs forimmediate restoration solutions

Marketing approvals obtained in Europe & N. America; full-marketrelease in Q1 2015

20

New generation BLT implant to be launched

1 iData and Straumann estimate

11

Charitable event using Straumann fixededentulous immediate solutions attracts attention

21

3-day charitable event at Afopidental campus near Paris involving 14 patients and 60 dental professionals

Patients received total immediate dental restorations (both jaws, with 6-8 Straumann BLT implants per jaw and fully functional full-arch provisional dentures) all in one day

22

New 3.3mm diameter ideal for narrow spaces in front of mouth

Complements 4.1mm PURE Ceramic Implant launched in Q1

Tooth-colored material for high-end esthetic, metal-free solution

High predictability, 100% tested

ZLA surface for enhanced osseointegration

First implants successfully placed in controlled MAT (market acceptance test) phase

To be presented at EAO in Rome in September

Small diameter Straumann ‘Pure’ Ceramic Implant

12

23

Straumann’s comprehensive implant portfolio

Tissue Level4mm short

implantBone Level Bone Level Tapered

PUREMonotype

SLA SLActive SLActive SLA SLActive SLA SLActive ZLA

Titanium1

Roxolid

Ceramic

Q1 20152

24

Straumann acquires 12% of RODO Medical, a privately-held developer of innovative implant restoration devices, in California

RODO’s Smileloc system

Uses a clip mechanism made of ‘shape memory’ alloy

Prosthetic crowns fixed without cement or screws

Convenient removal and replacement of prosthetic parts without damage

Innovative prosthetic anchorage

Crown

RODOdevice

Implant

13

25

Agreement signed in Q2 with Europe’s second largest supplier of oral tissue regeneration products

Exclusive distribution rights for extensive range of botiss products in most countries

Botiss co-distributes Emdogain® in Germany and takes over distribution in parts of Eastern Europe and Middle East

Call option to obtain up to 30% of botiss in 2017

Straumann to start selling botiss products in Europe in Q4; other regions to follow pending regulatory clearances

Collaboration with botiss – update

Increasing share in fast-growing geographies & segments

14

27

Growth of private hospital and practice segment expected to exceed public hospital segment, which Straumann leads

Agreement with former distributor Beijing Finest Medical Instrument Co. Ltd. to take over certain assets

fixed considerations of CHF 9mn plus variable consideration up to CHF 18mn depending on business performance until 2016

Greater control of business in China; access to distribution network, customers, market data etc.

Further sales growth through hybrid multi-distributor model approach

Significant investments to build a consultative sales force and local training-&-education organization with target of growing in private segment, where Straumann is under-represented

New hybrid multi-distributor model in China

28

Substantial investments in dynamic Asian markets

China (BJFM) MegaGen Biodenta Corp. DM Capital

Location ChinaKorea, international

presenceTaiwan/Switzerland,

international presenceChina

InvestmentConsideration up

to CHF 27mCHF 18m convertible

bonds (3% p.a.)1

CHF 6m +2m convertiblebonds (1% p.a.)

CHF 5m

Strategic rationale

Spur market sharegrowth in fast-growing

Chinese market – further focus on ‘private’

segment

Drive growth in fast-growing Asian and other

emerging markets

Provide comprehensivesolutions for dentists &

labs in value segment in emerging markets

Investment in dentistryfund with a focus on

China

15

Targeting unexploited growthmarkets

Multi-brand strategy to address premium and value segments

Brazil (49%) Germany (51%)

Taiwan Korea

Common platform fortechnology & production

Spain (30%)

Canada (44%)

Germany

Germany (100%)

USA (12.5%)

Premium Value

30

16

31

Instradent to drive and manage distribution and internationalization of Sraumann’s value business

Small dedicated team in Basel building up business in various countries, which will sell specific value brands, supported by common platform for technology and production

Subsidiaries already running in Spain and US (Neodent), and soon to launch in Italy

Introducing a new distribution platform…

Multibrand sales-flow to value segment

=Distributor 

CUSTOMER 

D D D 

D

D 

Other

Localsubs. 

32

17

33

Building a global presence in the value segment

Europe1 NAM LATAM APAC

Impl

ant s

yste

ms

Implants

Standard prosthetics

CADCAM

Abu

tmen

ts

Abutmentsfor 3rd partyimplants

Bars/bridgesfor 3rd partyimplants

Outlook

18

35

Straumann expects the global implant market to develop positively in 2014 and its revenue to grow in the low-single-digit range (l.c.).

Group will continue to invest in growth markets and its non-premium offering. Despite this, and thanks to last year’s cost-reduction measures, Straumann will deliver an expanded operating profit margin in 2014.

Mid-term it aims to achieve solid growth with further operating margin improvements.

Outlook 2014 unchanged Barring unforeseen circumstances

35

On track to restore comparable 2008 marginUnderlying EBIT margin

15-20%

2008 2012 2013 2015

14.5% 10-15%

18.2%

>20%

27.4%

Straumann Dental benchmark1

1 Peers comprise Nobel Biocare, Dentsply, Patterson, Henry Schein, Osstem, and Sirona.

10%

15%

20%

25%

36

10-15%

~20%@ today’s FX rates

10-15%

19

37

Questions & Answers

Calendar of upcoming events

2014

26 August 2014 First‐half conference Basel HQ

27 August Investor meetings Zurich

04 September Goldman Sachs Healthcare conference London

05 September  Investor meetings London

15 September  Investor meetings Frankfurt

23 October  Third‐quarter results  Webcast

20 November Credit Suisse Swiss Midcap conference Zurich

03 December Berenberg European conference Bagshot/London

04 December Investor meetings London

2015

27 February Full‐year 2014 results Basel HQ

3838 Results publication and corporate events. More information on straumann.com → Events

20

39

Straumann’s currency exposure

Cost breakdown 20131

Revenue breakdown 2013

1 These distribution charts represent the total net revenues and the total COGS as well as OPEX expenses in the various currencies. All numbers are rounded and based on 2013 figures.

Average exchange rates (rounded) FX sensitivity (+/- 10%) on...

FY 2013 YTD 2014 Revenue EBIT

EURCHF 1.23 1.22 +/- 25 million +/- 15 million

USDCHF 0.93 0.90 +/- 17 million +/- 7 million

JPYCHF 0.95 0.88 +/- 4 million +/- 2 million

39

EUR 40%

CHF 12%

USD / CAD / AUD 28%

Other 20%

EUR 21%

CHF 45%

USD / CAD /

AUD 22%

Other 12%

70

90

110

2013 2014

Development of Straumann’s main exchange rates since 2013

USDCHF EURCHF JPYCHF

Your contacts

Fabian Hildbrand

Corporate Investor Relations

Tel. +41 (0)61 965 13 27

Email investor.relations@straumann.com

Mark Hill Thomas Konrad

Corporate Communications

Tel. +41 (0)61 965 13 21 Tel. +41 (0)61 965 15 46

Email mark.hill@straumann.com Email thomas.konrad@straumann.com

40

21

International Headquarters

Institut Straumann AGPeter Merian-Weg 12CH-4002 Basel, SwitzerlandPhone +41(0)61 965 11 11Fax +41(0)61 965 10 01www.straumann.com